comparemela.com

Remegen Co News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88

YANTAI, China, June 3, 2024 /PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center

RemeGen Co Ltd Schedules 2023 Annual Meeting

RemeGen Co. Ltd. Class H (HK:9995) has released an update. RemeGen Co., Ltd. has announced its 2023 Annual General Meeting (AGM) scheduled for June.

RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren s Syndrome

RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing

RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Remegen Celebrates World Lupus Day 2024 With Increased Lupus Visibility Through Vital Knowledge Sharing

Remegen Celebrates World Lupus Day 2024 With Increased Lupus Visibility Through Vital Knowledge Sharing
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.